Roche Holding Company Profile (NASDAQ:RHHBY)

About Roche Holding (NASDAQ:RHHBY)

Roche Holding logoRoche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: NASDAQ:RHHBY
  • CUSIP: N/A
  • Web: www.roche.com
Average Prices:
  • 50 Day Moving Avg: $32.96
  • 200 Day Moving Avg: $30.58
  • 52 Week Range: $25.25 - $36.82
P/E:
  • Trailing P/E Ratio: 24.43
  • Foreward P/E Ratio: 16.86
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $52.98 billion
  • Price / Sales: N/A
  • Book Value: $3.53 per share
  • Price / Book: 9.69
Dividend:
  • Dividend Yield: 3.0%
Profitability:
  • EBIDTA: $20.76 billion
Misc:
  • Average Volume: 1.03 million shs.
 

Frequently Asked Questions for Roche Holding (NASDAQ:RHHBY)

What is Roche Holding's stock symbol?

Roche Holding trades on the NASDAQ under the ticker symbol "RHHBY."

Where is Roche Holding's stock going? Where will Roche Holding's stock price be in 2017?

7 brokers have issued 12 month price objectives for Roche Holding's shares. Their predictions range from $33.37 to $33.37. On average, they expect Roche Holding's share price to reach $33.37 in the next year. View Analyst Ratings for Roche Holding.

Who are some of Roche Holding's key competitors?

Who owns Roche Holding stock?

Roche Holding's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Fisher Asset Management LLC (0.00%), Parametric Portfolio Associates LLC (0.00%), Schafer Cullen Capital Management Inc. (0.00%), Bristol John W & Co. Inc. NY (0.00%), Riverbridge Partners LLC (0.00%) and Moody Lynn & Lieberson LLC (0.00%). View Institutional Ownership Trends for Roche Holding.

Who sold Roche Holding stock? Who is selling Roche Holding stock?

Roche Holding's stock was sold by a variety of institutional investors in the last quarter, including Bristol John W & Co. Inc. NY, Commerce Bank, Scout Investments Inc., Blair William & Co. IL, Cape Cod Five Cents Savings Bank, Tower Bridge Advisors, Wendell David Associates Inc. and Thomas White International Ltd.. View Insider Buying and Selling for Roche Holding.

Who bought Roche Holding stock? Who is buying Roche Holding stock?

Roche Holding's stock was acquired by a variety of institutional investors in the last quarter, including Parametric Portfolio Associates LLC, Moody Lynn & Lieberson LLC, Schafer Cullen Capital Management Inc., Fisher Asset Management LLC, Oxbow Advisors LLC, Kempner Capital Management Inc., Riverbridge Partners LLC and Sit Investment Associates Inc.. View Insider Buying and Selling for Roche Holding.

How do I buy Roche Holding stock?

Shares of Roche Holding can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Roche Holding stock cost?

One share of Roche Holding stock can currently be purchased for approximately $34.22.

Analyst Ratings

Consensus Ratings for Roche Holding (NASDAQ:RHHBY) (?)
Ratings Breakdown: 1 Sell Rating, 1 Hold Rating, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.57)
Consensus Price Target: $33.37 (2.48% downside)

Analysts' Ratings History for Roche Holding (NASDAQ:RHHBY)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/7/2017HSBC Holdings plcDowngradeHold -> ReduceLowView Rating Details
4/5/2017Cowen and CompanyUpgradeMarket Perform -> Outperform$25.25 -> $33.37LowView Rating Details
3/9/2017Liberum CapitalInitiated CoverageHold -> HoldLowView Rating Details
3/7/2017Barclays PLCInitiated CoverageOverweightN/AView Rating Details
2/19/2017Jefferies Group LLCReiterated RatingBuyN/AView Rating Details
12/7/2016Sanford C. BernsteinReiterated RatingOverweightN/AView Rating Details
8/3/2016Citigroup IncReiterated RatingBuyN/AView Rating Details
(Data available from 5/25/2015 forward)

Earnings

Earnings History for Roche Holding (NASDAQ:RHHBY)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Roche Holding (NASDAQ:RHHBY)
Current Year EPS Consensus Estimate: $1.91 EPS
Next Year EPS Consensus Estimate: $2.03 EPS

Dividends

Dividend History for Roche Holding (NASDAQ:RHHBY)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Roche Holding (NASDAQ:RHHBY)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Roche Holding (NASDAQ:RHHBY)
Latest Headlines for Roche Holding (NASDAQ:RHHBY)
Source:
DateHeadline
finance.yahoo.com logoWide-Moat Roche Is Undervalued
finance.yahoo.com - May 24 at 9:47 AM
seekingalpha.com logo3 Things In Biotech You Should Learn Today: May 11, 2017
seekingalpha.com - May 11 at 7:59 PM
finance.yahoo.com logoGenentech to Present New Data on Personalized Medicines and Cancer Immunotherapies at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
finance.yahoo.com - May 11 at 7:59 PM
finance.yahoo.com logoRoche Throws a New Wrinkle Into the IO Market
finance.yahoo.com - May 10 at 7:46 PM
finance.yahoo.com logoGenentech Provides Update on Phase III Study of TECENTRIQ (Atezolizumab) in People with Previously Treated Advanced Bladder Cancer
finance.yahoo.com - May 10 at 11:14 AM
finance.yahoo.com logoCancer Immunotherapy Fallout From Roche's Bladder Cancer Failure
finance.yahoo.com - May 10 at 11:14 AM
americanbankingnews.com logoRoche Holding Ltd. (RHHBY) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - May 9 at 12:14 PM
finance.yahoo.com logoThe Zacks Analyst Blog Highlights: Arcelor Mittal, Roche Holding AG and Cummins
finance.yahoo.com - May 9 at 10:47 AM
finance.yahoo.com logoRoche receives FDA approval for complementary PD-L1 (SP263) biomarker test in urothelial carcinoma
finance.yahoo.com - May 2 at 5:21 PM
finance.yahoo.com logoExelixis (EXEL) Posts Earnings in Q1, Cabometyx in Focus
finance.yahoo.com - May 2 at 5:21 PM
americanbankingnews.com logoRoche Holding Ltd. (RHHBY) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - May 2 at 2:20 PM
seekingalpha.com logoMorningstar: This Large Biotech Could Be The World's Best Stock
seekingalpha.com - May 1 at 6:50 PM
finance.yahoo.com logoFDA clears Roche high-volume immunoassay lab testing solution to support critical medical treatment decisions
finance.yahoo.com - May 1 at 10:18 AM
seekingalpha.com logoRoche Q1 2017: Strong Signals For Investors - Seeking Alpha
seekingalpha.com - April 28 at 3:42 PM
finance.yahoo.com logo[$$] Roche Revenue Up 4%
finance.yahoo.com - April 27 at 7:59 PM
finance.yahoo.com logoRoche Tops the Swiss Market After First Quarter Sales Beat Expectations
finance.yahoo.com - April 27 at 10:57 AM
finance.yahoo.com logoNew Data at AAN Reinforce Clinical Benefit of Genentech’s OCREVUS (Ocrelizumab) for Relapsing and Primary Progressive Multiple Sclerosis
finance.yahoo.com - April 26 at 5:43 PM
finance.yahoo.com logoIndia's antitrust watchdog orders probe into Roche cancer drug
finance.yahoo.com - April 26 at 5:43 PM
americanbankingnews.com logoRoche Holding Ltd. (RHHBY) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - April 20 at 12:58 PM
finance.yahoo.com logoGenentech to Present New Data at AAN Reinforcing Efficacy and Safety of Newly FDA Approved OCREVUS (Ocrelizumab) in Two Types of Multiple Sclerosis
finance.yahoo.com - April 19 at 9:35 AM
finance.yahoo.com logoRoche's (RHHBY) Cancer Drug Gets FDA Nod for Label Expansion
finance.yahoo.com - April 18 at 6:50 PM
finance.yahoo.com logoRoche's Hemophilia A Drug Positive in Second Phase III Study
finance.yahoo.com - April 18 at 9:30 AM
finance.yahoo.com logoFDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy, the Leading Cause of Blindness Among Working Age Adults in the United States
finance.yahoo.com - April 17 at 6:34 PM
finance.yahoo.com logoRoche's Genentech says its drug for diabetes complication has been approved by FDA
finance.yahoo.com - April 17 at 6:34 PM
finance.yahoo.com logoFDA Grants Genentech’s TECENTRIQ (Atezolizumab) Accelerated Approval as Initial Treatment for Certain People with Advanced Bladder Cancer
finance.yahoo.com - April 17 at 6:34 PM
finance.yahoo.com logoGenentech Announces Positive Interim Results for Emicizumab in Phase III Study of Children with Hemophilia A
finance.yahoo.com - April 17 at 9:17 AM
finance.yahoo.com logoRoche Launches Antibody Test to Diagnose Prostate Cancer
finance.yahoo.com - April 13 at 7:22 PM
finance.yahoo.com logoRoche launches new global Certified Provider Program for Target Enrichment in Genomic Sequencing
finance.yahoo.com - April 11 at 7:19 PM
finance.yahoo.com logo4 Reasons Why Roche Will Have the Best Growth in Big Pharma... and 1 Reason Why It Won't
finance.yahoo.com - April 11 at 7:19 PM
finance.yahoo.com logoPhase III Study Shows Genentech’s Alecensa® Was Superior to Crizotinib in a Specific Type of Lung Cancer
finance.yahoo.com - April 10 at 9:26 AM
americanbankingnews.com logoHSBC Holdings plc Lowers Roche Holding Ltd. (RHHBY) to Reduce
www.americanbankingnews.com - April 7 at 8:22 PM
americanbankingnews.com logoRoche Holding Ltd. (RHHBY) Upgraded to Outperform by Cowen and Company
www.americanbankingnews.com - April 6 at 12:24 AM
americanbankingnews.com logoRoche Holding Ltd. (RHHBY) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - April 5 at 3:42 PM
us.rd.yahoo.com logoRoche's Alecensa Succeeds in Lung Cancer Phase 3
us.rd.yahoo.com - April 3 at 7:05 PM
americanbankingnews.com logoRoche Holding Ltd. (RHHBY) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - April 3 at 12:55 PM
us.rd.yahoo.com logoHealthcare: Stock-Picking Increasingly Important as Valuations Rise
us.rd.yahoo.com - March 31 at 8:17 AM
us.rd.yahoo.com logoRoche's MS Drug Ocrevus Secures FDA Nod
us.rd.yahoo.com - March 29 at 8:47 PM
us.rd.yahoo.com logoFDA Advisory Committee Unanimously Recommends Approval of Genentech’s Subcutaneous Rituximab for Certain Blood Cancers
us.rd.yahoo.com - March 29 at 8:47 PM
us.rd.yahoo.com logoFDA Approves Genentech’s OCREVUS™ (Ocrelizumab) for Relapsing and Primary Progressive Forms of Multiple Sclerosis
us.rd.yahoo.com - March 29 at 12:24 AM
americanbankingnews.com logoRoche Holding Ltd. (RHHBY) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - March 28 at 12:33 PM
seekingalpha.com logoProtalix Biotherapeutics: High Expectations For Upcoming Phase 2 Cystic Fibrosis Readout
seekingalpha.com - March 27 at 9:26 AM
finance.yahoo.com logoShould Value Investors Pick Roche Holding (RHHBY)? - Yahoo Finance
finance.yahoo.com - March 25 at 12:22 AM
finance.yahoo.com logoFDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris
finance.yahoo.com - March 24 at 1:03 AM
moodys.com logoYestar Healthcare Holdings Company Limited -- Moody's: Yestar's 2016 results are in line with expectations
www.moodys.com - March 17 at 1:21 AM
finance.yahoo.com logoRoche launches the cobas® EGFR Mutation Test v2 for use with either plasma or tumor tissue samples
finance.yahoo.com - March 14 at 9:52 AM
finance.yahoo.com logoRoche Diagnostics recognizes Poplar Healthcare as Roche Molecular Center of Excellence
finance.yahoo.com - March 13 at 9:32 AM
thestreet.com logoEuropean Health Care Stocks Wobble After Trump Tweet on Drug Prices
www.thestreet.com - March 7 at 9:27 AM
wsj.com logoRoche Shares Boosted by Cancer Drug Trial Success
us.rd.yahoo.com - March 3 at 12:40 AM
seekingalpha.com logoRoche Shows More Fundamental And Technical Strength
seekingalpha.com - March 2 at 7:39 PM
us.rd.yahoo.com logo3:42 am Roche Hldg unit Genentech reports results from the Phase III APHINITY study for Perjeta met its primary endpoint
us.rd.yahoo.com - March 2 at 7:39 PM

Social

Chart

Roche Holding (RHHBY) Chart for Thursday, May, 25, 2017

This page was last updated on 5/25/2017 by MarketBeat.com Staff